Latest / WTR Small-Cap Spotlight
Solvonis Therapeutics: Redefining Treatment for Alcohol Use Disorder Through Capital-Efficient Innovation
Send us Fan Mail
In this episode of WTR Small-Cap Spotlight, Anthony Tennyson, CEO and Co-Founder of Solvonis Therapeutics (LSE: SVNS | OTC: SLVNF), joins host Tim Gerdeman, Vice Chair and Co-Founder of Water Tower Research, and analyst Robert Sassoon to discuss the company’s mission to transform care for addiction and mental health disorders.
Tennyson shares Solvonis’ journey from inception to its Phase 3 lead program for alcohol use disorder (AUD), which achieved 86% patient sobriety in prior Phase 2 trials, and details how the company’s **dual R&D strategy—repurposing existing molecules…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.